Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 15.46% is 30% below its 5-year average of 22.03%, near the low end of its 5-year range (8.83%–70.22%).
11.86% below its 12-month average of 17.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.90%.
GROSS MARGIN
15.46%
GROSS MARGIN AVG TTM
17.54%
GROSS MARGIN AVG 3Y
16.50%
GROSS MARGIN AVG 5Y
22.03%
GROSS MARGIN AVG 10Y
27.23%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-11.86%
CURRENT VS 3Y AVG
-6.29%
CURRENT VS 5Y AVG
-29.84%
CURRENT VS 10Y AVG
-43.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.82%
median of 678 covered companies
CURRENT VS SECTOR MEDIAN
-61.18%
vs the sector median at left
Market Cap
$173.76M
Gross Margin
83.01%
TTM Avg
91.50%
3Y Avg
95.75%
5Y Avg
97.17%
Market Cap
$174.99M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$176.16M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
Market Cap
$169.21M
Gross Margin
67.59%
TTM Avg
75.78%
3Y Avg
75.92%
5Y Avg
75.58%
Market Cap
$179.60M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$180.54M
Gross Margin
62.24%
TTM Avg
61.05%
3Y Avg
61.66%
5Y Avg
60.51%
Market Cap
$168.14M
Gross Margin
63.30%
TTM Avg
63.88%
3Y Avg
62.53%
5Y Avg
60.65%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediWound Ltd. (MDWD) | $172.00M | 15.46% | 17.54% | 16.50% | 22.03% |
| Nkarta, Inc. (NKTX)vs › | $173.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | 83.01% | 91.50% | 95.75% | 97.17% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.99M | 100.00% | 100.00% | 100.00% | 100.00% |
| Cue Biopharma, Inc. (CUE)vs › | $176.16M | 99.69% | 100.00% | -73.48% | -190.92% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | 67.59% | 75.78% | 75.92% | 75.58% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.60M | 0.00% | 50.00% | 25.00% | 16.67% |
| Journey Medical Corporation (DERM)vs › | $180.54M | 62.24% | 61.05% | 61.66% | 60.51% |
| OptimizeRx Corp. (OPRX)vs › | $168.14M | 63.30% | 63.88% | 62.53% | 60.65% |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | 63.55% | 56.95% | 54.72% | 65.55% |
Gross Margin
15.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 10.90% |
| 2026-03-31 | 21.90% |
| 2025-12-31 | 14.89% |
| 2025-09-30 | 16.50% |
| 2025-06-30 | 23.51% |
| 2025-03-31 | 18.66% |
| 2024-12-31 | 15.46% |
| 2024-09-30 | 15.55% |
| 2024-06-30 | 8.83% |
| 2024-03-31 | 12.23% |
| 2023-12-31 | 13.47% |
| 2023-09-30 | 18.76% |
| 2023-06-30 | 23.82% |
| 2023-03-31 | 21.74% |
| 2022-12-31 | 70.22% |
| 2022-09-30 | 41.94% |
| 2022-06-30 | 23.84% |
| 2022-03-31 | 33.13% |
| 2021-12-31 | 28.05% |
| 2021-09-30 | 38.53% |
| 2021-06-30 | 38.98% |
| 2021-03-31 | 41.32% |
| 2020-12-31 | 34.89% |
| 2020-09-30 | 41.81% |
| 2020-06-30 | 30.22% |
| 2020-03-31 | 27.72% |
| 2019-12-31 | 32.98% |
| 2019-09-30 | 22.78% |
| 2019-06-30 | 83.22% |
| 2019-03-31 | 33.41% |
| 2018-12-31 | 30.24% |
| 2018-09-30 | 55.01% |
| 2018-06-30 | 38.99% |
| 2018-03-31 | 26.73% |
| 2017-12-31 | 21.51% |
| 2017-09-30 | 54.26% |
| 2017-06-30 | 29.55% |
| 2017-03-31 | 37.04% |
| 2016-12-31 | -98.84% |
| 2016-09-30 | 8.49% |
| 2016-06-30 | -19.38% |
| 2016-03-31 | -59.06% |
| 2015-12-31 | -158.05% |
| 2015-09-30 | -707.84% |
| 2015-06-30 | -403.64% |
| 2015-03-31 | -161.19% |
| 2014-12-31 | -820.97% |
| 2014-09-30 | -1530.43% |
| 2014-06-30 | -1753.85% |
| 2014-03-31 | -240.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
